ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
Evopoint Biosciences Inc.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
BigHat Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Lumos Pharma
Verastem, Inc.
EMD Serono
Revolution Medicines, Inc.
UNC Lineberger Comprehensive Cancer Center
Recurv Pharma Inc
iOnctura
Erasca, Inc.
National Institutes of Health Clinical Center (CC)
Frontier Medicines Corporation
Beijing Biotech
Filamon LTD
University of Vermont
University of Virginia
AstraZeneca
NeoImmuneTech
Engeneic Pty Limited
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Lokon Pharma AB
Dana-Farber Cancer Institute
Intima Bioscience, Inc.
Amplia Therapeutics Limited
A2 Biotherapeutics Inc.
AstraZeneca
M.D. Anderson Cancer Center
Arvinas Inc.
Tasca Therapeutics
Essen Biotech
University of Southern California
MBrace Therapeutics
Xerient Pharma
Revolution Medicines, Inc.
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Auricula Biosciences Inc.
Bold Therapeutics, Inc.
Zhejiang Provincial People's Hospital
Takeda
Jacobio Pharmaceuticals Co., Ltd.